Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

In this single-group, phase 2 study, the use of trastuzumab deruxtecan resulted in a response in 60% of women with HER2-positive advanced breast cancer who had received a median of six previous lines of therapy. The drug was associated with myelosuppression and gastrointestinal toxicity; interstitia...

Full description

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 382; no. 7; pp. 610 - 621
Main Authors: Modi, Shanu, Saura, Cristina, Yamashita, Toshinari, Park, Yeon Hee, Kim, Sung-Bae, Tamura, Kenji, Andre, Fabrice, Iwata, Hiroji, Ito, Yoshinori, Tsurutani, Junji, Sohn, Joohyuk, Denduluri, Neelima, Perrin, Christophe, Aogi, Kenjiro, Tokunaga, Eriko, Im, Seock-Ah, Lee, Keun Seok, Hurvitz, Sara A, Cortes, Javier, Lee, Caleb, Chen, Shuquan, Zhang, Lin, Shahidi, Javad, Yver, Antoine, Krop, Ian
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 13.02.2020
Subjects:
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - adverse effects
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Antitumor activity
Body weight
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Camptothecin - administration & dosage
Camptothecin - adverse effects
Camptothecin - analogs & derivatives
Confidence intervals
Consolidation Chemotherapy
Cytotoxicity
DNA topoisomerase
Drug dosages
Epidermal growth factor
ErbB-2 protein
Female
Humans
Immunoconjugates - administration & dosage
Immunoconjugates - adverse effects
Immunotherapy
Intention to Treat Analysis
Kaplan-Meier Estimate
Lung diseases
Lung Diseases, Interstitial - chemically induced
Metastases
Metastasis
Middle Aged
Monoclonal antibodies
Myelosuppression
Nausea
Patients
Progression-Free Survival
Receptor, ErbB-2 - analysis
Receptor, ErbB-2 - antagonists & inhibitors
Targeted cancer therapy
Trastuzumab
Tumors
ISSN:0028-4793, 1533-4406, 1533-4406
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this single-group, phase 2 study, the use of trastuzumab deruxtecan resulted in a response in 60% of women with HER2-positive advanced breast cancer who had received a median of six previous lines of therapy. The drug was associated with myelosuppression and gastrointestinal toxicity; interstitial lung disease was reported in 13.6% of the patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa1914510